ASSEMBLY BIOSCIENCES, INC.
About ASSEMBLY BIOSCIENCES, INC.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $72.3M
- Net income
- -$6.1M
- Total assets
- $257.6M
- Market cap
- $453.8M
- Operating margin
- -16.8%
- Net margin
- -8.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $72.3M
- Operating expenses
- $84.4M
- Operating income
- -$12.1M
- Income tax
- $0
- Net income
- -$6.1M
- EPS (basic)
- $-0.55
- EPS (diluted)
- $-0.55
Balance sheet
- Total assets
- $257.6M
- Current assets
- $254.5M
- Total liabilities
- $50.8M
- Current liabilities
- $48.8M
- Shareholders’ equity
- $206.8M
Cash flow
- Operating cash flow
- -$41.1M
- Investing cash flow
- -$113.5M
- Financing cash flow
- $174.7M
- Net cash flow
- $20.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $453.8M
- EPS (diluted)
- $-0.55
- Shares outstanding
- 20.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 17, 2010
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $6.1M in FY2025.
- Revenue grew 1056% from FY2021 to FY2025.
- Trading 41% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ASSEMBLY BIOSCIENCES, INC..
Write a review
News about ASSEMBLY BIOSCIENCES, INC.
News & sentiment via Polygon.io
